Resources To Prevent Youth Vaping Act

1) What happened: On March 26, 2026, Sen. Shaheen (D-NH) introduced S.4257, the Resources To Prevent Youth Vaping Act, with five cosponsors (Murkowski-R, Durbin-D, Baldwin-D, Blumenthal-D). The bill was read twice and referred to the Senate HELP Committee. This is an early-stage bill with no companion in the House and no committee markup scheduled. 2) The money trail: This bill does NOT appropriate any funds. It amends Section 919(b) of the FD&C Act to raise the user fee collection ceiling for tobacco products from $712M (FY2019-2026 levels) to $826.2M in FY2027, then CPI-adjusted annually. User fees are assessed on manufacturers and importers based on market share by class (cigarettes, cigars, smokeless, roll-your-own, pipe tobacco, and starting FY2029, any deemed products including e-cigarettes, vaping devices, and oral nicotine pouches). The expansion to all deemed classes in FY2029 is the structural shift — it broadens the fee base, theoretically lowering per-unit fees on cigarettes if vaping and nicotine pouch volumes grow. 3) Winners and losers: Traditional cigarette manufacturers ($MO) face a modest dollar increase but may see their relative fee share decline as the base expands to include vaping products. Manufacturers of vaping and oral nicotine products face new fee obligations starting FY2029; Zyn ($PM) and Njoy/On! ($MO) are directly exposed. Pure-play vaping companies that are not publicly traded on US exchanges are most exposed. The bill is currently at early stage (referred to committee), with no House companion or scheduled markup, indicating low near-term passage probability in the 119th Congress. 4) Presidential action: The Apr 18, 2026 executive order on psychedelic therapies is unrelated to this bill. It does not amplify or conflict with the tobacco user fee structure. However, the executive order creates a separate tailwind for companies in the psychedelic therapeutics space ($CMPS, $MNMD, $GHRS, $ATAI, $CYBN), as it directs HHS and FDA to accelerate regulatory pathways for these treatments. 5) Timeline: The bill must clear the HELP Committee, pass the Senate (where it has bipartisan co-sponsors but no majority support guarantee), get a House companion, pass both chambers in identical form, and be signed into law. Given the early stage and narrow fee mechanism, passage before the 2026 midterm elections is unlikely. FY2027 fee changes would require enactment by Sept 30, 2026, to affect that fiscal year. Current legislative velocity is low — only two actions on the introduction date.